TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18981888
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) as final treatment
Study: 18981888
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical management (CMM) as final treatment
Study: 16622435
Drug: Neoadjuvant docetaxel-cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant docetaxel-cisplatin (docetaxel 85 mg m-2 on day 1, cisplatin 40 or 50 mg m-2 on days 1 and 2 for three 3-week cycles)
Study: 12594153
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg mixed with sodium bicarbonate 8.4% 2 ml
Study: 12594153
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg mixed with fentanyl 100 micro g
Study: 12594153
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg mixed with lidocaine 2%
Study: 12594153
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg mixed with normal saline
Study: 12594153
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg alone
Study: 10988281
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 to 16 mg once daily)
Study: 9238898
Drug: SofScale scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SofScale scaling gel
Study: 9238898
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (conventional toothpaste)
Study: 2409850
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketotifen orally
Study: 30523133
Drug: Top-down therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-down therapy
Study: 30523133
Drug: Accelerated step-up
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Accelerated step-up therapy
Study: 26260754
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of polyethylene glycol (SD-PEG)
Study: 22282264
Drug: New generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generic formulation of entecavir tablets (test)
Study: 22282264
Drug: Available branded
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available branded formulation of entecavir tablets (reference)
Study: 17187655
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day for </=6 months
Study: 11133904
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol (approximately 3 mg/day)
Study: 9610700
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg daily for either 2 or 5 years)
Study: 27676662
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Saline (1 mL)
Study: 27676662
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Calcitonin (50 IU)
Study: 25078304
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 12 weeks
Study: 24604476
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks
Study: 18391475
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (10 g/d, ALA intake 5.5 g/d)
Study: 18391475
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (placebo, 10 g/d)
Study: 14673725
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 600 mg daily for 6 months
Study: 15532695
Drug: Homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicine (Cantharis 30c)
Study: 1712524
Drug: ERU capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERU capsules (Radicis urticae) for 7 days
Study: 7002338
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 5656 rads in 28 fractions in 5 1/2 weeks (202 rads daily)
Study: 7002338
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 4352 rads in 12 unequal fractions in 4 weeks with 3 g/m2 oral misonidazole 4 hours before the 500-rad fraction, once a week for 4 weeks
Study: 31578113
Drug: Early video
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early video capsule
Study: 25860126
Drug: Carbetocin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (20 µg to 140 µg, adjusted based on previous patient's response)
Study: 25860126
Drug: Carbetocin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (140 µg)
Study: 24054343
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy (ART)
Study: 21377144
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for insomnia for AD (CBTI-AD, n=9)
Study: 21377144
Drug: Behavioral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral placebo treatment (BPT, n=8)
Study: 19614786
Drug: Uptitrated glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitrated glyburide (10 mg to 15 mg)
Study: 8080747
Drug: Chemotherapy response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy response (complete response, partial response, stable disease)
Study: 2975491
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of HBV vaccine (5 micrograms)
Study: 2975491
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of HBV vaccine (2 micrograms)
Study: 30921795
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of spa therapy (group 1)
Study: 30921795
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of spa therapy (group 2)
Study: 26499146
Drug: Peritoneal chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal chemotherapy with Lobaplatin (40 mg intraoperatively) followed by intravenous FOLFOX regimen
Study: 19207894
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with internal sinus lift (ISL) without graft material
Study: 19207894
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (native posterior maxilla implants)
Study: 19207894
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with ISL
Study: 17559913
Drug: Ecallantide (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide (5, 10, 20, or 40 mg/m² intravenously)
Study: 15040783
Drug: PMD3117 (Ang
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMD3117 (Ang I vaccine)
Study: 9658688
Drug: In situ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In situ teicoplanin treatment
Study: 9658688
Drug: Empirical amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Empirical amikacin therapy switched to teicoplanin
Study: 2649462
Drug: Misonidazole (MISO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (MISO; 11 g/m2)
Study: 322546
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 2.5 mg
Study: 25948027
Drug: Pharmacologic Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic Group (IV infusion of ephedrine 37.5 mg/h)
Study: 22954665
Drug: sorafenib (400mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400mg, orally, twice daily) plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Study: 22954665
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Study: 19186715
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment using acupoint group I (BL 15, BL 18, BL 20, BL 23) and acupoint group II (CV 4, CV 3, SP 6, KI 3, LR 3)
Study: 19186715
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment with Sailete tablets, 20 mg each tablet, one tablet each night
Study: 16984495
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.d. for 7 days
Study: 9102058
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement group (n = 14, mean calcium intake 1988 +/- 90 mg/day)
Study: 9102058
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 21, mean calcium intake 952 +/- 109 mg/day)
Study: 9102058
Drug: Non-compliant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-compliant group (n = 49, mean calcium intake 981 +/- 75 mg/day)
Study: 22549115
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus pioglitazone (15 mg every 12 h)
Study: 18848141
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg azimilide
Study: 18848141
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg azimilide
Study: 11755322
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg followed by an infusion of 6-10 mg/kg.hr(-1))
Study: 1092585
Drug: Bethanechol 25
Normalized name: bethanechol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol 25 mg
Study: 26135593
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam 1500 mg
Study: 26135593
Drug: Oral levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral levetiracetam 1500 mg
Study: 26135593
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous levetiracetam 1500 mg
Study: 18419721
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg IV intra-operatively with parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Study: 18419721
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g IV during surgery and 1 g PO for 7 days
Study: 18419721
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Study: 18419721
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg IV intra-operatively with paracetamol 1 g IV during surgery and 1 g PO for 7 days
Study: 14513808
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of finasteride
Study: 3514204
Drug: Vigabatrin (GVG)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (GVG) 3 g/day
Study: 31487218
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks
Study: 27990435
Drug: Supraclavicular brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Study: 27990435
Drug: Infraclavicular brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Study: 27990435
Drug: Axillary brachial
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary brachial plexus block with 20 mL ropivacaine 0.75%
Study: 24781895
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) supplementation (210 mL, 19.5-mmol nitrate)
Study: 23713082
Drug: BAY 94‐8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94‐8862 (2.5, 5, or 10 mg once daily)
Study: 22562554
Drug: BAY 94‐8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94‐8862 (2.5, 5, or 10 mg once daily or 5 mg twice daily)
Study: 22562554
Drug: Spironolactone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25-50 mg once daily)
Study: 16182674
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10, 20, and 30 mg
Study: 16182674
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10 to 30 mg/day
Study: 8932548
Drug: ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ofloxacin (400 mg twice a day for 5 doses)
Study: 8932548
Drug: procainamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: procainamide (1 g oral single dose)
Study: 1867179
Drug: Rifampin 300
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 300 mg twice daily for 5 days every 3 months
Study: 1867179
Drug: Rifampin treatment
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin treatment
Study: 31984508
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) treatment for 8 weeks, five sessions
Study: 27019511
Drug: Selective BRAF
Normalized name: Braftovi
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selective BRAF inhibitor (vemurafenib)
Study: 27019511
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (dabrafenib/trametinib)
Study: 27019511
Drug: Dabrafenib (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (alone or in combination)
Study: 14694352
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg b.i.d. alprazolam
Study: 14694352
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg b.i.d. alprazolam
Study: 14694352
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg b.i.d. lorazepam
Study: 14694352
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg b.i.d. lorazepam
Study: 10969298
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 1)
Study: 10969298
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 2)
Study: 10969298
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 3)
Study: 10969298
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml
Study: 9085317
Drug: Oral amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiloride (10 mg of amiloride 1‐mg/ml solution)
Study: 9085317
Drug: Nebulized amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized amiloride (4.5 ml of 1‐mg/ml solution in 12% saline)
Study: 9085317
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oral vs inhalation administration
Study: 8412202
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 4‐HPR daily for 52 weeks
Study: 3534992
Drug: Fluocortin butylester
Normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butylester (FCB) 4 mg daily
Study: 23527715
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg sodium hyaluronate
Study: 19491816
Drug: Velaxin (venlafaxine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velaxin (venlafaxine) 75 mg daily for 8 weeks
Study: 19491816
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antidepressants or antiepileptics)
Study: 16947783
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment (up to 25 mg per week orally) combined with folic acid
Study: 10849058
Drug: Cinnamon extract
Normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon extract (40 mg twice daily for 4 weeks)
Study: 8462917
Drug: Tannacomp (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tannacomp (500 mg of tannin albuminate and 50 mg ethacridine lactate), administered as 2 tablets three times a day for 5 days, followed by 5 days without treatment, then another 5 days of the same regimen.
Study: 3517701
Drug: Flurbiprofen 300
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 300 mg per diem for 14 days
Study: 3517701
Drug: Indomethacin 150
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 150 mg per diem for 14 days
Study: 30194992
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg weekly for 16 weeks
Study: 29097122
Drug: FT+TMP gel
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FT+TMP gel
Study: 29097122
Drug: FT+Acid gel
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FT+Acid gel
Study: 29097122
Drug: FT+9000 gel
Normalized name: lactase 9000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT+9000 gel
Study: 22356267
Drug: Selenomethionine (Seme)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (Seme) 200μg daily for 3 months (Se3), n = 15
Study: 22356267
Drug: Selenomethionine (Seme)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (Seme) 200μg daily for 6 months (Se6), n = 46
Study: 17875253
Drug: Healthy Children,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Children, Strong Families intervention promoting healthy eating and physical activity; details on dosage and duration not specified.
Study: 11553197
Drug: Nasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin (three preprandial doses combined with one evening subcutaneous NPH if needed)
Study: 11553197
Drug: NPH injections
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH injections (two daily)
Study: 7989953
Drug: Single-dose NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose NSAIDs
Study: 7989953
Drug: Low- and
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- and high-dose NSAIDs
Study: 7989953
Drug: Recommended and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended and supramaximal single doses of three NSAIDs
Study: 7989953
Drug: Weak opioids
Normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weak opioids (WO) alone or in combination (WO/C) with nonopioid analgesics
Study: 7989953
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of WO/C analgesics
Study: 7989953
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of NSAIDs
Study: 3171371
Drug: Prilocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 3% with felypressin 0.03 international units/ml
Study: 24724835
Drug: Topical benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzocaine
Study: 22744627
Drug: Metformin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin administration
Study: 17461735
Drug: Non-antiarrhythmic drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiarrhythmic drugs (beta-blockers, aldosterone antagonists, ACE inhibitors, angiotensin receptor-blockers, statins, omega-3 fatty acids)
Study: 17461735
Drug: Non-antiarrhythmic drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiarrhythmic drugs